MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Oncoplastic Reconstruction Versus Reduction Mammoplasty in Macromastia: Safety, Satisfaction, and Aesthetic Outcomes Compared

MedXY Editorial Team•Aug 25, 2026•news
Bilateral breast reductionOncoplastic breast reconstructionMacromastiapatient-reported outcomesphẫu thuật vú

Highlight

This study compares oncoplastic breast reconstruction (OP) and standard bilateral breast reduction (BBR) for macromastia management in women undergoing breast conservation surgery, assessing clinical safety, patient-reported quality of life, and aesthetic outcomes. OP shows comparable major complication rates to BBR, offers significant improvements in psychosocial, sexual, and physical well-being, and yields similarly high aesthetic satisfaction.

Study Background

Macromastia, characterized by excessively large breasts, often leads to physical discomfort, psychosocial distress, and can complicate breast cancer surgical management when breast-conserving surgery (lumpectomy) is indicated. Traditional bilateral breast reduction (BBR) has long been established to alleviate macromastia symptoms and improve quality of life by reducing breast volume symmetrically. Oncoplastic breast reconstruction (OP) represents an innovative approach that combines tumor excision with simultaneous volume reduction and soft tissue rearrangement. This approach aims not only to treat breast cancer but also to relieve macromastia symptoms and optimize breast symmetry and cosmetic outcomes after surgery. Despite the growing adoption of OP, limited data directly compares its clinical safety, patient-reported outcomes (PROs), and aesthetics with standard BBR in women with macromastia undergoing breast conservation.

Study Design

This retrospective cohort study was conducted at a single institution by a single experienced surgeon, including patients who underwent either oncoplastic reconstruction (OP) or bilateral breast reduction (BBR) from April 2022 to May 2025. The inclusion criteria centered on women with symptomatic macromastia, either with breast cancer requiring lumpectomy (OP group) or for symptomatic relief without cancer (BBR group). Clinical data extracted included demographics, operative details, complications, and postoperative follow-up. Patient-reported outcomes were measured using the BREAST-Q survey, encompassing psychosocial well-being, sexual well-being, physical well-being, and satisfaction with breasts. Aesthetic outcomes were independently evaluated in subsets of 10 patients per group using validated scales assessing six different aesthetic domains. Statistical analyses comprised univariate testing and analysis of covariance (ANCOVA) controlling for potential confounders such as age and body mass index (BMI).

Key Findings

The study cohort consisted of 180 patients, with 116 (64.4%) undergoing BBR and 64 (35.6%) undergoing OP. Patients in the BBR group were generally younger and had greater breast tissue resection weights, whereas the OP group exhibited higher BMI and American Society of Anesthesiologists (ASA) physical status classification, indicating a higher baseline surgical risk profile.

Clinical Safety: Wise pattern incision was used for the majority of cases — universally in BBR and 97% in OP. While minor wound breakdown was statistically more frequent in the OP group, potentially reflecting the more complex oncologic and reconstructive nature of the surgery, major complication rates did not differ significantly between groups. These findings highlight that OP, despite involving tumor excision, maintains an acceptable safety profile comparable to standard BBR.

Patient-Reported Outcomes: Both groups experienced significant postoperative improvements on the BREAST-Q across psychosocial, sexual, and physical well-being domains, as well as satisfaction with breast appearance. Importantly, after adjustment for age and BMI, these increases were comparable between OP and BBR cohorts, suggesting that the therapeutic benefits of breast tissue reduction extend similarly to patients undergoing oncologic reconstruction.

Aesthetic Outcomes: Aesthetic assessment in a selected subset revealed that BBR was marginally favored over OP across six evaluated aesthetic criteria, but the difference was less than 0.5 points on a Likert scale. This minimal difference suggests that OP achieves nearly equivalent cosmetic results, reflecting successful integration of tumor resection and breast reshaping techniques.

Expert Commentary

The integration of oncologic resection and plastic surgical principles inherent to oncoplastic reconstruction is a paradigmatic shift in breast cancer surgery, aiming to maintain oncologic safety while optimizing cosmesis and patient satisfaction. This study robustly supports OP as a safe and effective alternative to standard bilateral breast reduction in women with macromastia undergoing breast conservation. The finding of comparable major complications affirms the importance of surgical expertise in reducing adverse outcomes, particularly given the higher ASA scores in the OP cohort.

Minor wound issues being more frequent in OP might reflect the complexity of combining cancer surgery with reconstruction, underscoring the need for meticulous perioperative care. The equivalence in patient-reported outcomes across domains is encouraging, emphasizing that addressing both oncologic and symptomatic needs can substantially enhance quality of life. The near equivalence in aesthetics reflects advancements in oncoplastic techniques, allowing surgeons to preserve breast shape and symmetry effectively.

Limitations include the retrospective design, single-institution and surgeon experience, and relatively small sample for aesthetic comparison, which may limit generalizability. Future prospective, multicenter studies could validate these findings and explore long-term oncologic outcomes in larger, more diverse populations.

Conclusion

This study demonstrates that oncoplastic breast reconstruction, when integrated with lumpectomy in women with macromastia, offers significant improvements in quality of life comparable to those achieved by bilateral breast reduction. It maintains a favorable safety profile with similar major complication rates and yields high patient satisfaction and aesthetic results nearly equivalent to BBR. These findings support the expanding role of OP as a preferred reconstructive option in breast cancer patients requiring volume reduction, facilitating symptom relief without compromising oncologic or cosmetic outcomes.

Funding and ClinicalTrials.gov

No specific funding information or clinical trial registration was provided in the study abstract.

References

1. Oh SJ, Rodriguez J, Hu K, Allam O, Sullivan J, Glaspy J, Tannenbaum E, Berger ER, Butler PD. Comparing Clinical, Patient-Reported, and Aesthetic Outcomes of Oncoplastic Reconstruction Versus Reduction Mammoplasty in Macromastia. Plastic and reconstructive surgery. 2026 Aug 24. PMID: 42636447.

2. Clough KB, Kaufman GJ, Nos C, et al. Improving breast cancer surgery: a classification and quadrant per quadrant atlas for oncoplastic surgery. Ann Surg Oncol. 2010 May;17(5):1375-91.

3. Mansell J, Jallali N. Oncoplastic breast surgery: principles and practice. Breast 2010;19(5):368-71.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Impact of Anxiety and Depression on Patient-Reported Outcomes After Functional and Aesthetic RhinoplastyAnxiety and depression negatively influence satisfaction and revision rates after functional septorhinoplasty but do not affect outcomes following aesthetic septorhinoplasty.Oct 22, 2026Streamlining Male Torso Reconstruction Post-Massive Weight Loss: Insights from a 443-Patient SeriesA standardized unified surgical approach for male torso deformities after massive weight loss demonstrates safety, low complication rates, and marked patient satisfaction across 443 cases.Oct 13, 2026Minimally Invasive Breast Augmentation: Enhanced Recovery and Sensory Outcomes Compared to Hybrid TechniquesThis study evaluates patient-reported outcomes after minimally invasive breast augmentation (Mia) versus hybrid augmentation, demonstrating superior recovery, pain reduction, and nipple sensitivity with Mia, without compromising satisfactioSep 30, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Bridging Perspectives: Comparing Patient-Reported and Physician-Assessed Modified Rankin Scale Scores in Chronic Neurologic Disorders in Zambia
This study evaluates concordance between physician-assessed and patient-reported modified Rankin Scale scores in adults with chronic neurologic disorders in Zambia, revealing substantial agreement but highlighting cultural and symptomatic f
Sep 30, 2026
Sustained Benefits of a Multidomain Lifestyle Intervention in Multiple Sclerosis: Insights from the 24-Month LIMS Study Follow-UpThe LIMS study demonstrates sustained, modest improvements in MS-related functioning and dietary behavior up to 24 months following a digital multimodal lifestyle intervention, supporting lifestyle interventions as complementary to MS managSep 29, 2026
Advancing Treatment Evaluation in Progressive Multiple Sclerosis: Interim Patient-Reported Outcomes for MAMS Clinical TrialsThis article reviews the development and validation of patient-reported outcome measures as interim endpoints in multi-arm multistage trials for progressive multiple sclerosis, highlighting their potential to accelerate therapeutic developmSep 29, 2026